Virios Therapeutics, Inc. (VIRI) |
|
0.98 0.04 (4.26%)
|
09-27 11:31 |
|
Open: |
0.95 |
Pre. Close: |
0.94 |
|
High:
|
0.99 |
Low:
|
0.95 |
|
Volume:
|
31,297 |
Market Cap:
|
19(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 11:20:37 AM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.32  One year: 1.54 |
| Support: |
Support1: 0.82 Support2: 0.69 |
| Resistance: |
Resistance1: 1.13 Resistance2: 1.32 |
| Pivot: |
0.97 |
| Moving Average: |
MA(5): 0.94 MA(20): 1
MA(100): 1.41 MA(250): 0.78 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 43.7 %D(3): 37.3 |
| RSI: |
RSI(14): 42.4 |
| 52-week: |
High: 2.42 Low: 0.21 |
| Average Vol(K): |
3-Month: 582 (K) 10-Days: 168 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VIRI ] has closed below upper band by 48.8%. Bollinger Bands are 75% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.95 - 0.96 |
0.96 - 0.96 |
|
Low:
|
0.9 - 0.91 |
0.91 - 0.91 |
|
Close:
|
0.93 - 0.94 |
0.94 - 0.95 |
|
Company Description |
|
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia. |
Headline News |
Mon, 18 Sep 2023
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement - Yahoo Finance
Tue, 12 Sep 2023
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023 - Yahoo Finance
Mon, 21 Aug 2023
Is Virios Therapeutics Inc (VIRI) a Leader in the Biotechnology Industry? - InvestorsObserver
Mon, 14 Aug 2023
Virios Therapeutics Announces Halt to At-The-Market Offering Sales - Yahoo Finance
Sat, 12 Aug 2023
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call Transcript - Yahoo Finance
Tue, 25 Jul 2023
Virios Therapeutics Inc (VIRI) Up 1.86% in Premarket Trading - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
19 (M) |
| Shares Float |
16 (M) |
|
% Held by Insiders
|
12.4 (%) |
|
% Held by Institutions
|
8.3 (%) |
|
Shares Short
|
465 (K) |
|
Shares Short P.Month
|
590 (K) |
Stock Financials |
|
EPS
|
-0.32 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.25 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-67.7 |
|
Return on Equity (ttm)
|
-128.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-8 (M) |
|
Levered Free Cash Flow
|
-5 (M) |
Stock Valuations |
|
PE Ratio
|
-3.17 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.92 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.49 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
